BRAF and metastatic melanoma: Thus, depending on the class of kinase activation, MEKi currently remains an important therapeutic option for metastatic melanoma patients with an activating non-V600 BRAF mutation who have failed or are not eligible for immune checkpoint inhibitors in the first line.